Acne is a skin condition that results from clogged skin openings and pores, including hair follicles. Most people who tend to follow this order are teenagers and people in their early 20s. Regardless of age or skin type, anyone can be afflicted by this common skin condition. This kind of skin condition is treated with retinoids and antibiotics.
Acne vulgaris affects 9.4% of people worldwide, with adolescents having the highest prevalence rates. It affects over 90% of men and 80% of women across all ethnic groups. According to the American Academy of Dermatology Association, acne affects 50 million Americans annually, making it the most common skin condition in the nation. The article continued by stating that 85% of people between 12 and 24 experience mild acne. Furthermore, according to prevalence data from a dermatology clinic in a teaching hospital in Varanasi, between the ages of 12 and 17, 50.6% of boys and 38.13% of girls experienced acne.
Due to better information-based decision-making, improved patient-physician relationships, and well-documented procedures, there is an increased demand for treatments for facial and skin problems. The adoption of numerous, less painful aesthetic combination therapy procedures results from this. In addition, the growing demand for quicker treatments and results is expected to increase demand for equipment-based procedures like lasers. Marketing and advertising have been extremely helpful in promoting both current and upcoming acne treatments. Due to online and offline campaigns promoting ideal beauty standards, people have bought more cosmetics. The demand for creams and lotions that treat acne has also recently increased.
Americas is the most significant shareholder in the global acne treatment market and is expected to grow at a CAGR of 5.06% during the forecast period. This can be attributed to the region's high prevalence of skin conditions like acne, the release of fresh goods, and technological advancements. According to the American Academy of Dermatology Association, nearly 85% of teenagers experience acne during adolescence, and over 50 million Americans suffer. Additionally, in the US, the cost of treating acne among those who sought medical attention in 2013 surpassed USD 1.2 billion. These factors are expected to drive market growth over the forecast period.
Europe is expected to grow at a CAGR of 4.65% during the forecast period. Europe held the second-largest share of the acne treatment market in 2022 due to its highly developed medical sector and businesses' organic growth strategies. The region's acne treatment market is growing due to significant players' focus on innovative product launches and developments. For instance, in August 2020, the Italian pharmaceutical company Cassiopea SpA declared that the US FDA had approved its Winlevi (clascoterone cream 1%) for treating acne. Galderma, a Swiss pharmaceutical company specializing in dermatological treatments and skin care products, announced the topical retinoid trifarotene 0.005%. AKLIEF has received approval from the US FDA for treating acne vulgaris. These organic growth strategies can help businesses strengthen their position in the European market.
The global acne treatment market’s major key players are GlaxoSmithKline Plc, Almirall S.A, Galderma Laboratories, L.P, Hoffman La Roche Ltd, Bausch Health Companies Inc, Leo Pharma A/S, Johnson & Johnson Services Inc, Teva Pharmaceutical Industries Ltd, Candela Corporation, and VYNE Therapeutics Inc.